172 related articles for article (PubMed ID: 19718615)
1. Pheochromocytomas, PASS, and immunohistochemistry.
Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
[TBL] [Abstract][Full Text] [Related]
2. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
3. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies.
Portela-Gomes GM; Stridsberg M; Grimelius L; Falkmer UG; Falkmer S
APMIS; 2004 Oct; 112(10):663-73. PubMed ID: 15601318
[TBL] [Abstract][Full Text] [Related]
4. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
5. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
6. The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.
Babinska A; Sworczak K; Wisniewski P; Nałecz A; Jaskiewicz K
Exp Clin Endocrinol Diabetes; 2008 Apr; 116(4):246-51. PubMed ID: 18393131
[TBL] [Abstract][Full Text] [Related]
7. [Role of immunohistochemical study of extracellular matrix components in the estimation of the malignant potential of adrenal pheochromocytomas].
Bezuglova TV; Poliakova GA; Kazantseva IA
Arkh Patol; 2008; 70(6):19-21. PubMed ID: 19227276
[TBL] [Abstract][Full Text] [Related]
8. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
[TBL] [Abstract][Full Text] [Related]
10. Development of differential diagnosis for benign and malignant pheochromocytomas.
Gao B; Kong F; Xu Z
Int J Urol; 2008 Sep; 15(9):771-7. PubMed ID: 18651863
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.
Nagura S; Katoh R; Kawaoi A; Kobayashi M; Obara T; Omata K
Mod Pathol; 1999 Dec; 12(12):1107-11. PubMed ID: 10619262
[TBL] [Abstract][Full Text] [Related]
12. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
13. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
14. [Distinction between benign and malignant pheochromocytomas].
Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism.
Cadden IS; Atkinson AB; Johnston BT; Pogue K; Connolly R; McCance D; Ardill JE; Russell CF; McGinty A
Histopathology; 2007 Dec; 51(6):743-51. PubMed ID: 17916073
[TBL] [Abstract][Full Text] [Related]
16. Distinct expression of galectin-3 in pheochromocytomas.
Gimm O; Krause U; Brauckhoff M; Hoang-Vu C; Dralle H
Ann N Y Acad Sci; 2006 Aug; 1073():571-7. PubMed ID: 17102125
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
[TBL] [Abstract][Full Text] [Related]
18. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
Helman LJ; Cohen PS; Averbuch SD; Cooper MJ; Keiser HR; Israel MA
J Clin Oncol; 1989 Nov; 7(11):1720-5. PubMed ID: 2809684
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms.
Mlika M; Kourda N; Zorgati MM; Bahri S; Ben Ammar S; Zermani R
Tunis Med; 2013 Mar; 91(3):209-15. PubMed ID: 23588637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
